About the Company:   Akari Therapeutics is a clinical-stage biopharmaceutical company. The company specializes in the treatment of the orphan autoimmune and inflammatory diseases by the means of innovative therapeutic which includes mainly complement (C5) and leukotriene (LTB4) pathways. The company was established in 2015, is headquartered in London, England. Akari Therapeutics is majorly funded by 7 investors. Venrock and Vivo Capital are the most recent investors.
Stock Analysis: NASDAQ: AKTX at https://www.webull.com/quote/nasdaq-aktx has shown the peak performance in the month of June (considering the duration of the last 3 months). During the peak performance, the price was 2.610, and the volume was 1,77,847. The opening at 10:21 08/18 EDT was 1.860, and the previous close was also at the same price of 1.860. The volume was 35.86K and the Market Capital at that time was 62.26M and the low, for the time being, was 1.850. While the 52-week low was …